Submitted by Sabin on
Day 1 - Wednesday, 7 July, 2004
8:00 | Registration
8:30 | Introduction and Announcements - Ciro de Quadros
8:35 | Welcome Remarks - Julio Frenk, Jon Andrus
8:45 | Key note address: Health, economics and poverty – Immunization as a development priority - David Bloom
9:30 | The Need for Rotavirus Vaccines – A View from the International Community - Roger Glass
Session I. Epidemiology & Disease Burden
Convenors: Roger Glass & Miguel O’Ryan
10:00 | The Global Epidemiology of Rotavirus Disease - Umesh Parashar
10:15 | Overview of the Asian Rotavirus Surveillance Network - Paul Kilgore
10:30 | Overview of the African Rotavirus Surveillance Network - George Armah
10:45 | Discussion
11:00 | BREAK
11:30 | Rotavirus Surveillance in 11 countries of Latin America - Miguel O'Ryan
11:45 | Disease and Economic Burden of Rotavirus in Mexico - Romeo Rodriguez, Raul Velazquez
12:05 | Population-based Surveillance of Rotavirus in Brazil - Alexandre Linhares
12:20 | Rotavirus Epidemiology in Venezuela - Irene Perez-Schael
12:35 | Questions & Discussion
1:00 | LUNCH
Session II. Virology, Pathogenesis, and Immunity
Convenors: Harry Greenberg & Carlos Arias
2:00 | Global Perspective on Rotavirus Strains - Jon Gentsch
2:15 | New Insights in the Pathogenesis of Rotavirus Disease - Richard Ward
2:30 | Immunity against Rotavirus Disease - Harry Greenberg.pdf
2:45 | Correlates of Protection Against Rotavirus Disease - Guillermo Ruiz-Palacios
3:00 | Discussion
3:15 | BREAK
Session III. Past Experience with Rotavirus Vaccines
Convenors: Ruth Bishop & Irene Perez Schael
3:45 | History of Rotavirus Vaccine Development - Timo Vesikiari
4:15 | Reappraisal of association between Rotavirus Vaccine and Intussuception - Lone Simonsen
4:30 | Is Intussusception Likely with Other Rotavirus Vaccines? - Paul Offit
4:45 | Discussion
Day 2 - Thursday, 8 July, 2004
Session IV. Results with New Rotavirus Vaccines
Convenors: Timo Vesikari and Alexandre Linhares
9:00 | Phase III evaluation of the Merck bovine rotavirus vaccine - Penny Heaton
9:45 | Phase III evaluation of the GlaxoSmithKline human live-attenuated vaccine - Beatrice de Vos
10:30 | Discussion
10:45 | BREAK
11:15 | Other vaccine approaches - UK Bovine Vaccine - Albert Kapikian, Rhesus vaccine - Leonard Ruiz, Neonatal Vaccines (RV3, 116E, & I321) - Ruth Bishop, Inactivated Rotavirus Vaccines & VLPs - BaomingJiang & Osamu Nakagomi
12:15 | Discussion
12:30 | LUNCH
2:00 | Regulatory Opportunities for rotavirus vaccines and novel licensing strategies - Liliana Chocarro
2:20 | Questions and Discussion
Session V. From Vaccine to EPI Implementation
Convenor: Ciro A. de Quadros and José Ignacio Santos
2:45 | Health economics of universal Rotavirus vaccination in Latin America & Carribbean - Dagna Constenla
3:15 | Discussion
3:30 - BREAK
4:00 | Financing mechanisms for low and low-middle income countries--GAVI - Ruth Levine
4:20 | Accelerating Vaccine Development and Introduction: The Role of Public-Private Partnerships - John Wecker
4:30 | Communication Strategies for Rotavirus Vaccines - Heidi Larson
4:45 | Discussion
Day 3, Friday 9 July, 2008
Session V. Roundtable: Perspectives in Vaccine Introduction — The Role of Public/Private Partnerships
Conveners: Jon Andrus and Roberto Tapia
9:00 | Participation of Ministers of Health present at the meeting - Steve Landry - The Vaccine Fund, Jon Andrus - PAHO Revolving Fund, Tore Godal - GAVI, InterAmerican Development Bank, World Bank, Steve Wiersma - World Health Organization, Jean Stephenne - GSK, Adel Mahmoud - Merck and Co., Inc.
11:00 | General Discussion
11:30 | Concluding Remarks